ADIPOQ and metabolic disease: Moreover, even though we did not detect significant changes in circulating LEPTIN and ADIPONECTIN, we found significant decrease in ADIPSIN, another adipokine, linked to increased fat mass and adipose tissue dysfunction in metabolic disorders (26), at 6M of T therapy.